
Biology of Lung Injury, Development of Novel Therapeutics, and Medical Preparedness

Eleanor M. Summerhill, Gary W. Hoyle, Sven-Eric Jordt, Bronwen J. Jugg, James G. Martin, Sadis Matalon, Steven E. Patterson, David J. Prezant, Alfred M. Sciuto, Erik R. Svendsen, Carl W. White, and Livia A. Veress; on behalf of the ATS Terrorism and Inhalational Disasters Section of the Environmental, Occupational, and Population Health Assembly

This Official Workshop Report of the American Thoracic Society (ATS) was approved by the ATS, April 2017

Abstract

This report is based on the proceedings from the Inhalational Lung Injury Workshop jointly sponsored by the American Thoracic Society (ATS) and the National Institutes of Health (NIH) Countermeasures Against Chemical Threats (CounterACT) program on May 21, 2013, in Philadelphia, Pennsylvania. The CounterACT program facilitates research leading to the development of new and improved medical countermeasures for chemical threat agents. The workshop was initiated by the Terrorism and Inhalational Disasters Section of the Environmental, Occupational, and Population Health Assembly of the ATS. Participants included both domestic and international experts in the field, as well as representatives from U.S. governmental funding agencies. The meeting objectives were to (1) provide a forum to review the evidence supporting current standard medical therapies, (2) present updates on our understanding of the epidemiology and underlying pathophysiology of inhalational lung injuries, (3) discuss innovative investigative approaches to further delineating mechanisms of lung injury and identifying new specific therapeutic targets, (4) present promising novel medical countermeasures, (5) facilitate collaborative research efforts, and (6) identify challenges and future directions in the ongoing development, manufacture, and distribution of effective and specific medical countermeasures. Specific inhalational toxins discussed included irritants/pulmonary toxicants (chlorine gas, bromine, and phosgene), vesicants (sulfur mustard), chemical asphyxiants (cyanide), particulates (World Trade Center dust), and respirable nerve agents.

Copyright © 2017 by the American Thoracic Society
Originally Published in Press as DOI: 10.1513/AnnalsATS.201704-297WS on April 18, 2017
Internet address: www.atsjournals.org

Contents
Overview
Introduction
Methods
Inhalational Lung Injury: Exposure Risks, Epidemiology, and Standard Therapies
The Government’s Role in Countermeasure Development: Funding, Resources, and Regulatory Environment Challenges to Developing and Distributing Novel Pharmacologic Therapies
Methods and Approaches to Understanding Mechanisms of Lung Injury and Discovering New Therapeutic Targets
Epidemiologic Research: Graniteville, South Carolina Chlorine Gas Release and World Trade Center Disaster
Animal Models of Inhalational Lung Injury: Pathologic Mechanisms and Possible Targets
Chlorine Bromine Phosgene
The role of transient receptor potential (TRP) ion channels in acute airway injury Cyanide Sulfur mustard Respirable nerve agents
Discussion: Ongoing Challenges and Recommendations
Overview

The American Thoracic Society (ATS) workshop on toxic inhalational lung injury was cosponsored by the ATS and National Institutes of Health (NIH) Countermeasures Against Chemical Threats (CounterACT) program. Since 2006, CounterACT has taken a leadership role in pursuing the development of new and improved medical countermeasures against chemical threat agents through basic, translational, and clinical research. Agents of highest interest are determined by the U.S. Department of Homeland Security. The 2012 Chemical Terrorism Risk Assessment list is available online (1).

The workshop took place at the 2013 ATS International Conference meeting in Philadelphia, Pennsylvania. It was initiated by members of the Terrorism and Inhalational Disasters (TID) section of the Environmental, Occupational, and Population Health Assembly (EOPH). The goals were to (1) provide a forum to review the evidence supporting current standard medical therapies, (2) present updates on our understanding of the epidemiology and underlying pathophysiology of inhalational lung injuries, (3) discuss innovative investigative approaches to further delineating mechanisms of lung injury and identifying new specific therapeutic targets, (4) discuss promising novel medical countermeasures, (5) facilitate collaborative research efforts, and (6) identify challenges and future directions in the ongoing development, manufacture, and distribution of effective and specific medical countermeasures. The principal findings and recommendations of the panel after participant presentations and group discussion were as follows:

- Although general supportive therapies extrapolated from treatment of a number of different clinical syndromes including acute respiratory distress syndrome (ARDS), reactive airways dysfunction (RADS), and bronchiolitis obliterans (BO) remain the mainstay of treatment for toxic inhalational lung injuries, the field has advanced significantly. A better understanding of the underlying basic pathophysiology of lung injury after a number of different toxic exposures has resulted in the discovery of novel specific therapeutic targets leading to promising new compounds currently in the process of further development.
- Novel antidotes of particular interest in preclinical development in large-animal models include R-107, a novel antioxidant countermeasure for inhalational chlorine toxicity; dimethyl trisulfide, cobainamide, and sulfanegen for the treatment of cyanide poisoning; and intratracheal tissue plasminogen factor to counter toxic airway effects of sulfur mustard (SM) inhalation.
- Significant challenges to ongoing research in this field include the relative rarity and unpredictability of toxic inhalational events as well as the inherent ethical constraints restricting research and testing in humans. The following key priorities were thus delineated:
  - Continued development of appropriate animal models, realistic exposure mechanisms, and incorporation of standard therapies into both the control and therapeutic intervention groups
  - Development of U.S. Food and Drug Administration (FDA)–qualified animal models facilitating collaborative use, head-to-head comparisons of efficacy, and validation of results under identical experimental conditions
  - Extrapolation of pathophysiological mechanisms from other models of human lung injury and fostering of collaboration with scientists investigating these similar patterns of lung injury
  - Further development of global infrastructure for both acute and long-term cohort studies in exposed populations after toxic inhalational exposures
  - Linking lessons learned in the field to improved therapeutic strategies and identification of additional areas for basic scientific and translational investigation
- Despite significant governmental support for ongoing basic scientific research, preclinical trials, and development of novel agents, this funding stream is subject to changes in policy based on ever-changing intelligence information and public and governmental perception of need.
- Additional challenges to the development and distribution of effective, specific targeted therapies include the time and expense required to obtain FDA approval; development of therapeutic formulations that will enable rapid administration in the field, or that will still be effective despite a significant time delay; and the need to obtain the significant financial investment required for manufacture, marketing, and distribution from the pharmaceutical industry.

Introduction

To respond effectively to inhalational emergencies, clinicians and public health personnel must first have an understanding...
of mechanisms of lung injury, clinical sequelae, and appropriate medical management. Accidental or intentional release of respiratory toxins within a civilian population may cause mass casualties, rapidly overwhelming regional health care systems. With a growing understanding of exposure risk and increased funding and support from governmental agencies, the field of inhalational toxicology is significantly advancing. This workshop provided a venue for researchers and leaders in the field to review our current understanding of the biology of inhalational lung injury, discuss advances in the management of specific inhalational injuries, and define future goals and research priorities.

Within this broad field, we focused primarily on (1) inhaled irritants/pulmonary toxicants including chlorine gas, bromine, and phosgene; (2) vesicants, or blistering agents, such as mustards and lewisite; (3) the chemical asphyxiant hydrogen cyanide; (4) particulates in the form of World Trade Center (WTC) dust; and (5) respirable nerve agents such as insecticides, sarin, V-agents, soman, and tabun. Despite the Chemical Weapons Convention of 1993, these agents remain a significant threat. Stockpiling and use by some nations have continued, manufacture of certain agents is relatively easy, and many of these compounds are common industrial agents subject to accidental release.

Methods

Fourteen invited panelists participated in the workshop at the ATS International Conference in 2013. Two additional panelists provided materials for the final report. The panel included both domestic and international experts in the fields of inhalational toxicology, epidemiology, and pulmonary and critical care medicine, as well as representatives from U.S. governmental research funding agencies. Twelve of the participants are members of the TID section of the EOPH Assembly of the ATS. Six are funded by the NIH CounterACT program. Participants were selected on the basis of their knowledge, research interests, and/or track record of publication in the content areas. After the workshop, each participant submitted a summary of their presented material. These contributions, workshop discussions, and interval updates are summarized here. Follow-up meetings of the writing committee occurred during ATS Conferences in 2014, 2015, and 2016. All participants disclosed potential conflicts of interest before the workshop, which were managed according to the policies and procedures of the ATS. Before publication, all authors updated their conflict of interest disclosures and also provided updated content and references.

Inhalational Lung Injury: Exposure Risks, Epidemiology, and Standard Therapies

Inhalational lung injury may occur through the accidental or intentional release of chemical vapors, particulates, and/or incomplete products of combustion. Clinical manifestations of these agents are related not only to dose and proximity of exposure, but also to compound solubility or particulate size. Highly soluble compounds (ammonia) and larger particles (>10 μm) primarily affect the upper airway with rapid symptom onset. Intermediate-solubility agents such as chlorine and bromine and intermediate-sized particulates (5–10 μm) cause greatest injury between the larynx and segmental bronchi, but may also cause parenchymal injury, particularly in high concentrations. The smallest bronchi, bronchioles, and alveoli are targeted by poorly soluble compounds such as phosgene (CG) and particulate matter less than 5 μm in size (2–5). The role of neuronal sensory fiber transient receptor potential (TRP) ion channels in acute airway injury related to lung damaging agents was also discussed.

Acute manifestations of respiratory injury include upper airway obstruction, vocal cord dysfunction, acute respiratory distress syndrome (ARDS), and reactive airways dysfunction (RADS), an asthma-like syndrome characterized by airway hyperresponsiveness after a single massive inhalational event, which may persist for months or longer. Chronic syndromes may include chronic rhinosinusitis, or reactive upper airways syndrome (RUDS), irritant-induced asthma caused by multiple low-level exposures over time, bronchiolitis obliterans (BO), chronic obstructive pulmonary disease (COPD), sarcoidosis, eosinophilic pneumonia (EP), and other interstitial lung diseases. Finally, accelerated decline in lung function may occur (5–7).

Immediate treatment is based on the general precepts of personal protective equipment for first responders, removal of victims from the area, decontamination, and supportive care. Certain compounds, such as nerve agents and cyanide, which are not primarily lung-damaging agents, do have specific antidotes, although further optimization is needed (2, 5, 8). General supportive respiratory care includes warm, humidified oxygen, antitussives, and bronchodilators. Endotracheal intubation and low tidal volume mechanical ventilation may be necessary for airway compromise, copious secretions, and/or hypoxic respiratory failure secondary to ARDS. Injuries caused by intermediate-solubility agents are similar to those caused by smoke and thermal inhalational sequelae. Bronchoscopic lavage may be necessary to maintain airway patency because of epithelial injury and sloughing. Inhaled and/or systemic corticosteroids have been used as treatments for irritant and vesicant injuries. These management strategies have been extrapolated from treatments for other forms of airway injury or pulmonary disease, and supported in humans only through anecdotal reports and small, uncontrolled studies (2, 5, 8–10). The unpredictability of inhalational events and ethical constraints of studying human populations remain among the largest ongoing challenges faced by researchers. For these reasons, advances in the field have often been driven by findings in rodent and large-animal models.

The Government’s Role in Countermeasure Development: Funding, Resources, and Regulatory Environment

In the United States, development and distribution of medical countermeasures are coordinated by the Assistant Secretary for Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS) through the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) (Figure 1). As part of the PHEMCE, the NIH supports basic and preclinical research to identify mechanisms and targets of chemical
threats, design animal exposure models, and develop novel therapeutic strategies through the Countermeasures Against Chemical Threats (CounterACT) program.

Currently funded research focuses on countermeasures development against chemical warfare agents (e.g., sulfur mustard, sarin), toxic industrial chemicals (e.g., chlorine, cyanide), pesticides (e.g., parathion), and other chemicals. Important research collaborations exist with Contract Research Organizations (CROs) and the Department of Defense (DOD), including the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD, Aberdeen Proving Ground, MD). Under HHS, the Biomedical Advanced Research and Development Authority (BARDA) supports ongoing development and regulatory approval of novel countermeasures, providing infrastructure for manufacture and distribution.

The U.S. Food and Drug Administration (FDA) has issued regulatory guidelines for countermeasures research, summarized under the “Animal Rule,” which guides the drug approval process when human efficacy studies are unethical (11). In this case, the FDA approves drugs on the basis of animal efficacy studies alone, generally with two animal models, with human safety evaluation under existing requirements. Examples of countermeasures approved under the Animal Rule include the Cyanokit (hydroxocobalamin) for treatment of cyanide poisoning; levofloxacin for plague; raxibacumab, a monoclonal antibody directed against inhalational anthrax; and botulinum antitoxin.

Challenges to Developing and Distributing Novel Pharmacologic Therapies

Despite this support, major challenges remain in accelerating countermeasures development and improving collaborative efforts between basic and translational scientists, industry, and government stakeholders. Research priorities are ever-changing. Limited human data, often involving a single individual or small cohort, are often the only information available for animal model development and extrapolation of mass causality injuries. Therefore, ongoing population studies after large-scale disasters remain essential.

Methods and Approaches to Understanding Mechanisms of Lung Injury and Discovering New Therapeutic Targets

Epidemiologic Research: Graniteville, South Carolina Chlorine Gas Release and World Trade Center Disaster

In January 2005, an early morning train accident released approximately 54,000 kg of chlorine gas in the small town of Graniteville, South Carolina. Other than 180 millworkers on-shift, Graniteville was asleep. Because of topography and weather, the gas plume initially settled within a bowl-shaped depression (12–14). Millworkers and most residents were told to shelter-in-place. Many fled anyway, either driving quickly through or becoming trapped in the plume. Three exposure durations were therefore defined: (1) very short-term (1–5 min), (2) short-term (~10–15 min), and (3) long-term exposures of those who sheltered in place (~30–60 min). Exposure doses varied from lethal (>1,000 ppm) to the harmless odor threshold (0.2 ppm). Emergency callers frequently reported bleaching of their own clothes or surrounding objects. The plume was about 1.5 km wide at severe concentrations (>20 ppm) (14–16).

Eight of nine immediate fatalities occurred on site. All died of asphyxiation or acute respiratory failure, with pulmonary edema found on autopsy (17). The most severely injured (n = 71) were admitted, with one death several weeks after hospital discharge. All presented with pulmonary complaints, some also with cardiac, ocular, otorhinolaryngeal, gastrointestinal, and dermal. A clinical review of the patients who received both spirometry and chest X-ray in the hospital found that patients presented with a predominantly restrictive lung function pattern (18). Patients were treated with a variety of therapies, including β-agonists; ipratropium bromide; inhaled, oral, or intravenous corticosteroids; antibiotics; and nebulized or intravenous sodium bicarbonate in decreasing frequency. Five hundred and twenty-nine people were treated and released from emergency departments, and 331 more sought medical care at physician’s offices (17). The horror of the event affected the emotional health of the community as well (19, 20). Long-term follow-up of the known 1,384 victims is on-going (21–24).

Preliminary evidence demonstrates significantly reduced lung volumes in the severely exposed (25).

After the September 11, 2001 WTC attacks in New York City, the subsequent fire and collapse of the twin towers and nearby buildings resulted in massive release of products of combustion and pulverized building materials throughout lower Manhattan. Aerosolized toxins included polycyclic aromatic hydrocarbons, dioxins,
and volatile organic compounds. The dust was composed of numerous materials including crushed concrete, gypsum, asbestos, polychlorinated biphenyls, hydrochloric acid, silica, and heavy metals. These materials combined to make the dust highly alkaline (pH > 10). Approximately 5% of the dust particles were respirable (26).

The majority of first responders, including Fire Department of New York (FDNY) firefighters, were not wearing protective face masks. Epidemiologic studies of downstream pulmonary effects were greatly facilitated by the fact that firefighters were already being closely monitored with serial pulmonary function testing by the FDNY Bureau of Health Services. Multiple studies of sequelae in firefighters have been published, and summarized by Yip and colleagues (27). A syndrome that became known as WTC cough was described, most prevalent in those with the highest levels of exposure. Sixty-three percent of those with WTC cough had significant bronchodilator response and 24% had bronchial hyperresponsiveness (28). A high proportion demonstrated prolonged evidence of bronchial hyperresponsiveness consistent with RADS (29). This has persisted 12–13 years later (30). Another study demonstrated that exposure to WTC dust caused an average 372-ml decrease in FEV1 during the year after September 11, consistent with RADS (29). This has persisted 12 years (31, 32). These findings have persisted over 13 years (30, 33). Other pulmonary effects included eosinophilic pneumonia, sarcoidosis, tracheobronchomalacia, and possibly BO (34, 35). Nonpulmonary toxicities included reactive upper airways syndrome, vocal cord polyps, gastroesophageal reflux disease, obstructive sleep apnea, cancers, and systemic autoimmune diseases (28, 34–38).

Animal Models of Inhalational Lung Injury: Pathologic Mechanisms and Possible Targets

Chlorine. Chlorine gas (Cl2) is one of the most common toxic inhalational injuries. It is manufactured in large quantities for a variety of industrial uses, putting populations at risk through industrial accidents and spills during transport. Exposures are also encountered in the paper industry, swimming pools, and through mixing of domestic cleaning products (10, 39). Although most exposures are accidental, chlorine has been used as a warfare agent since World War I, and most recently on civilian populations in the Syrian civil war. Chlorine is highly toxic by inhalation, leading to dyspnea, hypoxemia, airway obstruction, pneumonitis, and pulmonary edema (39). Chlorine is an immediately water-soluble agent, causing damage from the upper airways to the alveolar compartment. Acute exposures may lead to airway mucosal sloughing, RADS, acute lung injury (ALI), and ARDS (40). Factors such as respiratory syncytial viral infection have been shown to potentiate Cl2-induced lung injury (41).

Animal models in multiple species including mice, rats, rabbits, pigs, sheep, and dogs (42–49) have been developed to study mechanisms of chlorine toxicity and response to potential therapies. Acute effects of chlorine inhalation documented in animal models include dyspnea or altered breathing patterns (50, 51), inflammation and mitochondrial damage (42, 43, 51, 53), impaired surfactant function (45, 54), hypoxemia (45, 47, 48), fluid leak and pulmonary edema (45, 47, 55, 56), lipid peroxidation (51, 57), changes in gene expression (58), induction of unfolded protein response (59), pulmonary hypertension (47), and airway hyperreactivity (AHR) (42, 44, 60–62). Later effects of chlorine inhalation include abnormal epithelial repair (60), airway fibrosis (49, 52, 63, 64), mucus overproduction (60), and altered lung function including AHR and fixed obstruction (44, 60, 63, 65, 66). In addition, exposure to chlorine has been shown to cause significant cardiotoxicity (67, 68).

Multiple therapeutic strategies have shown success in treating acute chlorine injury in animal models: antioxidants including dimethylthiourea (57), AEOL 10150 (69), N-acetylcysteine (70), and ascorbic acid plus deferoxamine (71); cAMP-elevating agents such as R-formoterol (62) and rolipram (72); antiinflammatory agents such as corticosteroids (66, 73–75) and triptolide (60); nitric oxide–modulating agents including nitrite (51, 76) and 1400W (42), a potent, selective nitric oxide inhibitor; neutrophil depletion (77); aerosolized heparin (78); and high molecular weight hyaluronan (79). The role of TRP channel inhibitors in acute lung injury secondary to chlorine and other toxic inhalational agents is becoming more clear, and TRP inhibitors have been shown to suppress pulmonary inflammation in this setting (80, 81). Current challenges include translating promising findings in preclinical models into countermeasures for human use and identifying interventions to reverse or prevent long-term effects of chlorine inhalation. R-107, a novel nitric oxide donor, peroxynitrite modulator, and superoxide scavenger, was shown to ameliorate Cl2-induced ARDS in an ovine model via the intramuscular route (82). The work was initially funded by CounterACT and is now moving forward in a collaborative effort between BARDA and industry.

Bromine. World production of bromine (Br2) exceeds 300,000 tons per year. A reddish liquid at room temperature, highly volatile bromine must be transported in specifically designed noncorrosive containers. As with chlorine, large populations may be exposed after transportation and industrial accidents. On September 1, 2011, in Chelyabinsk, Russia 42 people were hospitalized and more than 200 sought medical attention after a train derailment. Facilities producing Br2 are considered high risk for terrorist attacks by the Department of Homeland Security. One such attack was attempted in Israel in 2004 (83).

Bromine inhalation results in bronchospasm, AHR, ALI/ARDS, and death from respiratory failure. Long-term effects include RADS and pulmonary fibrosis (84). At present, only standard supportive care is available for treatment. Clearly, there is a need for additional research to develop specific therapies that target the basic mechanisms by which Br2 and its reactive intermediates damage the lungs.

Free hemoglobin and heme catalyze the generation of reactive intermediates that cause extensive injury to proteins, lipids, and DNA. Significant levels of free heme were detected in bronchoalveolar lavage (BAL) fluid, lung tissues, and plasma of mice exposed to Br2 gas, originating most likely from ruptured red blood cells. Postexposure administration of hemopexin, a heme-scavenging protein, decreased lung injury and improved survival (84). Further studies demonstrated that humanized transgenic mice overexpressing heme oxygenase-1 (HO-1), the first and rate-limiting step in heme degradation into iron, carbon monoxide.
(CO), and biliverdin (85), were significantly protected from exposure to Br₂ (84). Conversely, mice lacking HO-1 were sensitive to Br₂ and died much earlier of respiratory failure compared with wild-type controls (84). These are the first studies delineating the role of heme in ARDS caused by Br₂. On the basis of these findings, attenuating heme may prove useful in treating ARDS secondary to Br₂ inhalation.

**Phosgene.** Phosgene (CCl₂O) caused the greatest number of chemical deaths during World War I. Those exposed develop ALI/ARDS after an initial asymptomatic latent period. Phosgene (CG) is an important industrial chemical produced globally in large quantities. Because of the amount produced, ease of manufacture, and high toxicity, accidental or deliberate (terrorist-related) release resulting in mass casualties is of concern. Histologic damage occurs at doses greater than 30 ppm-min, and clinical pulmonary edema becomes evident above 150 ppm-min. The estimated human LD₅₀ is 500 ppm-min (86).

The mechanisms of action of CG are not fully understood. There are no proven therapeutic strategies or evidence-based guidelines for the management of CG-induced injury. Continuing research is therefore necessary. Two mechanisms of action have been proposed. The first postulates hydrolysis to hydrochloric acid (HCl). However, as insufficient HCl is produced within the lower airways to overcome the natural buffering capacity of lung tissue, this mechanism appears unlikely. Alternatively, as a highly electrophilic, hydrophobic gas, CG penetrates readily into the lower respiratory tract, directly affecting the respiratory epithelium. It reacts with a wide variety of nucleophilic biological tissue components through acylation reactions with primary and secondary amines, hydroxyl, and sulfhydryl groups. This causes the downstream release of arachidonic acid mediators such as leukotrienes and up-regulation of oxidative response enzymes. Damage to the respiratory epithelium causes disruption of the alveolar–capillary interface, moving fluid and inflammatory cells into the alveoli. CG also causes lipid peroxidation and surfactant damage (86).

Development of therapeutic approaches has traditionally been based on hypothetical pathways elucidated through in vivo research. Examples include supportive care modalities such as lung-protective ventilation (87, 88) and pharmacologic interventions such as steroids and bronchodilators (89, 90). This approach has been used in the terminally anesthetized pig model of CG-induced ALI (91). More recently, genomics analysis has identified specific cellular and molecular events that can be targeted by novel therapeutic interventions (92–94). Using Ingenuity pathway analysis of microarray data, Holmes and colleagues proposed a new putative mechanism of CG injury based on direct free radical attack on neuronal, endothelial, and epithelial cells resulting in tissue destruction and mediator release (95). Such approaches have led to experimental therapeutic strategies targeting neuronal signaling, receptors involved in the endothelin pathway, and receptors/proteins involved in Ca²⁺ signaling. Thus, an improved understanding of CG mechanisms of action at the cellular level may lead to the identification of novel therapeutic compounds. Although small animals have been used to screen candidate therapies, such as the antiinflammatory agents angiopoietin-1, which suppresses NF-κB and p38 mitogen-activated protein kinase (MAPK) pathways (96); 1400 W, a selective nitric oxide synthase-2 (NOS-2) inhibitor (97); ulinastatin, a urinary trypsin inhibitor (98); and mesenchymal stem cell transplantation (99, 100); and have demonstrated efficacy, further testing in large-animal models more relevant to human exposures is still needed.

The role of transient receptor potential (TRP) ion channels in acute airway injury. Noxious airborne chemicals are detected by the trigeminal and vagal sensory nerves of the airways, eyes, and skin. These neurons initiate respiratory reflexes including cough, sneezing, and decreased respiratory rate; sensations of irritation and pain; and glandular secretions (80). These responses may be protective, and help diminish the toxic effects of chemical threats. However, neuronal activation can lead to severe pain and respiratory distress resulting in incapacitation (101), further exposure, and injury. In particular, chlorine gas, capsaicin (in pepper spray), acrolein (in smoke), and tear gas agents (chlorobenzylidene malononitrile [CS] and chloroacetophenone [CN]) trigger strong neuronal irritant responses (80).

TRP ion channels are key airway noxious chemical receptors (102). TRP channels conduct calcium ions and other cations, initiating neuronal excitation and subsequent physiological responses. These channels are expressed in the chemosensory fibers of the trigeminal nerve, innervating the upper airways, and in vagal sensory fibers innervating the larynx and lower airways. TRPV1, the receptor for capsaicin, is expressed in the majority of chemosensory fibers. TRPV1 is also activated by acidic stimuli and noxious heat. TRPA1 is expressed in a smaller subset of chemosensory fibers and detects a wide range of chemical threats (102). TRPA1 was initially identified through its sensitivity to mustard oil (allyl isothiocyanate), the pungent ingredient in mustard, horseradish, and wasabi (103). Later studies found that TRPA1 is the neuronal target of acrolein, a major irritant in cigarette smoke; methyl isocyanate, the toxic and highly irritating chemical released in the Bhopal, India incident in 1984; and chlorine gas (104–106). Tear gas agents (CN, CS, and dibenzoxazepine [CR]) are the most potent activators of TRPA1. TRPA1-deficient mice are insensitive to the acute irritant effects, underscoring the important role of this ion channel. TRPA1 inhibitors attenuated behavioral pain responses to CN and CS, and reduced the inflammatory response, likely through inhibition of neurogenic inflammatory mechanisms (105).

TRPV4 expressed in pulmonary tissue has been shown to be a crucial mediator of ventilator and heart failure–associated lung injury (107–109). The effects of two novel TRPV4 inhibitors were examined in mice exposed to chlorine and hydrochloric acid, the first modeling acid fume exposure and the second acid aspiration injury. In both models, postexposure treatment with TRPV4 inhibitors reduced pulmonary inflammation by diminishing neutrophils, macrophages, and associated chemokines and cytokines, while decreasing histopathologic evidence of injury. TRPV4 inhibitors reduced vascular and epithelial leakage, airway hyperreactivity, and airway elastance, while improving blood oxygen saturation. Chlorine-exposed TRPV4-deficient mice showed diminished inflammation (81).

These studies have firmly established TRP ion channels as molecular targets of noxious chemical exposures and revealed
novel TRP channel–mediated mechanisms of tissue injury. On the basis of this rapidly advancing understanding, the health risks of chemical exposures to tear gas and capsaicin-based riot control agents need to be reevaluated.

**Cyanide.** Cyanide in the form of hydrogen cyanide (HCN), or cyanide anion salts, has been an archetypal poison through the ages. Exposure to HCN at concentrations of 200 to 500 ppm for 30 minutes or an ingestion of less than 1.0 mg/kg is usually fatal. Human exposures typically result from improperly prepared cassava, smoke inhalation, industrial accidents, and clinical use of nitroprusside. Animal models for antidote efficacy testing and advanced preclinical antidotes are discussed here.

Current countermeasures approved for use in the United States include a combination of nitrites, sodium thiosulfate, and hydroxocobalamin. These require intravenous administration, which is suboptimal in a mass casualty setting. This has fueled efforts to develop novel cyanide countermeasures suitable for rapid administration, such as intramuscular injection. Three antidotes in preclinical development include dimethyl trisulfide (110–114), cobinamide (115–118), and sulfanegen (119–123). Animal models have included the Nagasawa sublethal mouse (119), the Boss lethal mouse (115), the Brenner sublethal rabbit (116, 120), and lethal models developed by Borron and colleagues (121, 124, 125).

Dimethyl trisulfide is a natural product that converts cyanide to thiocyanate. It has been successfully administered as an intramuscular formulation in murine and rabbit models (110–114). Cobinamide is a biosynthetic precursor to hydroxocobalamin. Cobinamide detoxifies cyanide, forming a tight, stable complex with 2 moles of cyanide, which is then excreted in urine. The efficacy of cobinamide has been demonstrated in *Drosophila,* murine, and rabbit models (115–118). Sulfanegen is a produg of 3-mercaptopropyruvate (3-MP), formed by cysteine transamination. Release of 3-MP from sulfanegen detoxifies cyanide via transfer of the 3-MP sulfur to 3-MP sulfur transferase as a persulfide. The resulting enzyme-bound persulfide reacts with cyanide, generating the less toxic thiocyanate, excreted in urine. Intramuscular sulfanegen efficacy has been demonstrated in pig and rabbit models (119–123). In addition, the combination of sulfanegen and cobinamide shows promise (126, 127). Key developments in the above-mentioned antidotes are the development of novel formulations (113, 127, 128) that improve solubility, stability, and bioavailability.

**Sulfur mustard.** The vesicant and cytotoxic agent sulfur mustard (bis-2-chloroethyl sulfide; SM) is the most widely used chemical weapon in history (129, 130). Because of remaining stockpiles and ease of manufacture, SM continues to be a significant threat, and has been used by Islamic State militants (131–133). After acute inhalation, airway injury may lead to rapid deposition of fibrin plugs or casts, obstructing the airways. ALI/ARDS also occur. These toxic effects can lead to acute respiratory failure and death, and have been documented in both humans and animal models (134–137). Long-term complications include airway and parenchymal fibrosis.

Decontamination in the field aimed at dermal and ocular injury are initial priorities. There are no specific therapies currently approved for the treatment of pulmonary inhalational injuries. As definitive mass casualty treatment may be delayed, development of medical countermeasures for acute and chronic pulmonary sequelae with effectiveness hours or even days after exposure are a high priority. For example, during the Iran–Iraq War, victims of SM inhalation often did not reach tertiary care centers for days to weeks (137).

Studies have shown that in the setting of acute inhalational lung injury, the coagulation system is activated in the airways and alveoli, leading to increased procoagulant and decreased fibrinolytic effects. Activation of the coagulation system in extravascular sites such as the airways requires local expression of tissue factor, a process that occurs mainly in the microparticle fraction of airway fluids (138). Tissue factor pathway inhibitor inhibits these actions (139). In addition to local factors favoring coagulation after SM inhalation, antifibrinolytic systems, including plasminogen activator inhibitor-1, thrombin-activatable fibrinolysis inhibitor, and α2-antiplasmin, are also activated in the injured airway (140), leading to persistence of casts. Direct administration of tissue plasminogen factor into airways can eliminate or reverse airways obstruction by fibrin, and prevent gas exchange abnormalities and respiratory failure (135, 136). These therapies for the acute process might be complemented by catalytic antioxidants (141), flavonones (142), and/or cell-based therapies (143).

Human survivors of acute SM inhalation may later develop chronic fibrotic processes of the airways and lung parenchyma, including BO (144) and interstitial fibrosis (145–147). Research in the field is currently underway to study whether more recently developed antifibrotic therapies will be beneficial in preventing these crippling outcomes (148, 149). Effective treatment of SM pulmonary injury may require therapies directed at the acute processes leading to airway coagulation and ALI/ARDS as well as chronically applied therapies directed at airway and parenchymal fibrosis.

**Respirable nerve agents.** Nerve agents are organophosphate compounds that block acetylcholinesterase (AChE) at the neuronal junction. Organophosphates are widely used as insecticides, resulting in accidental poisonings in many parts of the world. Production and stockpiling for weaponized use have been forbidden in multiple treaties, most recently the Chemical Weapons Convention of 1993. Nevertheless, there have been multiple instances of use in civilian populations over the past few decades, most recently in Syria (150).

Traditional nerve agents (TNAs) bind and functionally disable AChE. This leads to overstimulation of muscarinic and nicotinic receptors. This overstimulation causes multiple pulmonary, cardiac, and neurologic effects resulting in acute respiratory failure due to bronchoconstriction, bronchorrhea, and respiratory muscle weakness; neurologic effects including muscle weakness, seizures, and coma; cardiovascular instability; and death. After decontamination, standard combination autoinjectable treatment kits used by the U.S. military (MARK-1) include the anticholinergic agent atropine, which competitively binds to the post-synaptic muscarinic receptor, and pralidoxime chloride, which reactivates AChE (151).

Nerve agent exposure may occur through the skin or via inhalation of vapor. Highly volatile sarin (GB) and soman (GD) are G-agents. Highly volatile sarin (GB) and soman (GD) are G-agents. Inhaled G-agents cause significant respiratory problems within minutes of exposure. V-agents VX and VR are classified as nonvapor hazards. This may not be appropriate, as these agents can
penetrate airways by attaching to inhaled dust, mist, and fog particles.

In the past, TNA studies focused on seizure activity after subcutaneous injection. More recent models include other, more realistic exposure routes, and have demonstrated additional forms of pulmonary toxicity. GB is distributed to the brain, kidney, liver, and blood plasma of mice (152, 153). Inhaled GB causes weight loss, pulmonary edema, hypoxemia, increased airway resistance, and increased minute ventilation in guinea pigs (154), with immediate inhibition of AChE activity noted in BAL fluid (155). Another study showed that the respiratory toxicity of GB, VX, and GD was independent of neuromuscular effects.

Selection of appropriate animal species and methods of exposure to accurately model human lung injury in the field remains challenging. This is due to differences in airway structure and anatomy between species, minute ventilation at the time of injury, and the need for pain and sedative medications and alternative routes of administration to ensure humane treatment. These necessary interventions have the potential to alter sites of injury, inflammatory mediators, antioxidant production, and physiological parameters. Standard treatments likely to be used by clinicians must be incorporated into efficacy trials as well. Animal models can now undergo an FDA qualification process, providing a resource for collaborative use between multiple centers, allowing comparison of efficacy in identical settings, and independent validation of findings.

Discussion: Ongoing Challenges and Recommendations

The field of inhalational toxicology and the development of specific countermeasures have moved forward considerably with the support of government, military, and private funding. Nevertheless, significant challenges remain. Ongoing priorities include (1) continued development of small- and large-animal models mimicking human exposure and inhalational lung injury, (2) extrapolation from human models of similar injury, (3) the development of effective novel agents that can be administered in a feasible manner postexposure, (4) addressing the time and expense required to obtain FDA approval, (5) working with industry to facilitate bringing new devices and pharmaceutical agents to market, including improved personal protective equipment that does not require fit-testing, provides protection for extended time periods, allows for easy decontamination, and increases user comfort and communication ability, and (6) further developing appropriate infrastructure for epidemiologic research in the setting of mass casualty events on national and international levels.

Selection of appropriate animal species and methods of exposure to accurately model human lung injury in the field remains challenging. This is due to differences in airway structure and anatomy between species, minute ventilation at the time of injury, and the need for pain and sedative medications and alternative routes of administration to ensure humane treatment. These necessary interventions have the potential to alter sites of injury, inflammatory mediators, antioxidant production, and physiological parameters. Standard treatments likely to be used by clinicians must be incorporated into efficacy trials as well. Animal models can now undergo an FDA qualification process, providing a resource for collaborative use between multiple centers, allowing comparison of efficacy in identical settings, and independent validation of findings.

As results of animal studies are sometimes not reproducible, these head-to-head comparisons and validation studies will be key across the NIH and BARDA. Genomic approaches may lead to an improved understanding of underlying pathophysiological processes and lead to the discovery of novel therapeutic targets. Computational modeling of lung injury is being used in the study of blast injury and ARDS, and there may be role for computational modeling in the study of inhalational toxin injury as well. Enhanced fostering of collaborative efforts between researchers in the field with scientists investigating patterns of lung injury such as ARDS, RADS, and BO from other etiologies is also imperative, as many pathways of injury overlap, and therapeutic targets may be similar.

Novel therapies require up to 10 years or more to achieve FDA approval, with more recent cost estimates in excess of $800 million (162). Expenses for chemical threat countermeasures may be somewhat less, as efficacy trials are conducted primarily in animals. However, large-animal studies, which more closely model humans, are costly. If the drug is already approved for another disease and/or route of administration, that may also contain costs. However, because use for chemical threats is a relatively low-probability event, as compared with blockbuster indications, pharmaceutical companies may not be motivated to sponsor FDA approval for this additional use. Getting novel compounds to market has been facilitated in some cases not only by BARDA, but by smaller pharmaceutical companies and nonprofit institutions.

Finally, linking lessons learned in the field from the DoD and nongovernmental organizations to knowledge learned in the laboratory setting will continue to be of the utmost importance. Investment in epidemiologic infrastructure and protocols for cohort studies, registries, and tissue banking for “fast on feet” study of both short- and long-term consequences of acute mass chemical exposures will be key factors in helping to improve future response (163). The NIH Disaster Research Response Program (DR2) was initiated in 2013 under the auspices of the National Institute of Environmental Health Sciences (NIEHS) and the National Library of Medicine (NLM) in 2013. Goals include developing a roster of subject experts who can be contacted after a disaster; advance development of research infrastructure and data collection tools; integrating research into preparedness, response, and recovery systems; and facilitating expedited institutional review board approval and funding for epidemiologic research after a disaster (164).

Because inhalation disasters and chemical threats remain real, a continued awareness of public need is necessary. Even with the combined resources of the NIH, HHS, and the DoD, the costs of countermeasure development and FDA approval are challenging. It requires
Members of the writing committee are as follows

**ELEANOR M. SUMMERHILL, M.D. (Co-Chair)**
**LIVIA A. VERESS, M.D. (Co-Chair)**
**GARY W. HOYLE, Ph.D.**
**SVEN-ERIC JORDT, Ph.D.**
**BRONWEN J. JUGG, Ph.D.**

**JAMES G. MARTIN, M.D.**
**SADIE MATALON, Ph.D.**
**STEVEN E. PATTHERSON, Ph.D.**
**DAVID J. PREZANT, M.D.**
**ALFRED M. SOUTTO, Ph.D.**
**ERIK R. SVENDSEN, Ph.D.**
**CARL W. WHITE, M.D.**

Workshop Participants

- Eleanor M. Summerhill, M.D. (Co-Chair); Livia A. Veress, M.D. (Co-Chair); Michael Gunn, M.D.; Gary W. Hoyle, Ph.D.; Sven-Eric Jordt, Ph.D.; Bronwen J. Jugg, Ph.D.; George Leiklauf, Ph.D.; James G. Martin, M.D.; Srikanth Nadapur, Ph.D.; Steven E. Patterson, Ph.D.; David J. Prezant, M.D.; Daniel Salemo, M.D.

Author disclosures


Acknowledgment

S.M. would like to acknowledge the contributions of Saurabh Aggarwal, Adam Lam, and Nilam Vetal, L.A.V. and C.W.W. would like to acknowledge the contributions of Raymond D. Rancourt.

References

consequences of the world trade center disaster. Environ Health Perspect 2004;112:731–739.


139 Rancourt RC, Veress LA, Ahmad A, Hendry-Hofer TB, Rioux JS, Garlick RB, White CW. Tissue factor pathway inhibitor prevents airway obstruction, respiratory failure and death due to sulfur


